The Royal Marsden launches AI radiology platform to revolutionise cancer care
Ella Day | May 27, 2025 | News story | Analytical & Laboratory Services, Market & Product Development, Medical Education, Research and Development | AI, CARPL.ai., Institute of Cancer Research, NTT DATA, National Institute for Health and Care Research, Oncology, The Royal Marsden, oncology, radiology
The Royal Marsden, a world-leading cancer research centre, has launched a large-scale, AI-powered radiology platform designed to accelerate cancer detection and treatment using medical imaging. This marks a major milestone in the application of AI for cancer research.
The technology will develop and evaluate AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This intends for faster response times, more accurate diagnoses and treatments that are more targeted.
The platform has been collaboratively developed by NTT DATA, which has built a machine operating platform (MLOps) and offers specialist imaging AI consulting services, and CAPRL.ai, an AI and MLO platform.
In response to growing recognition of the potential of AI to enhance the speed and accuracy of identifying imaging biomarkers, the development of the service was funded by the UK’s National Institute for Health and Care Research, the UK’s largest funder of health research.
It will be used for research at The Royal Marsden and the Institute of Cancer Research, including projects in collaboration with other research teams.
“By working with NTT DATA and CARPL.ai, we’ve created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS,” said Dow-Mu Koh, professor in functional cancer imaging and consultant radiologist in functional imaging at The Royal Marsden.
Tom Winstanley, chief technology officer at NTT DATA UK & Ireland, commented: “This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare.”
Ella Day
27/5/25
Related Content
NIHR chief scientific adviser visits Huddersfield health innovation campus
Professor Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and …
Liverpool launches £20m lab for infectious disease drug discovery
A new £20m high-security laboratory using robotics, artificial intelligence (AI) and human organoids to accelerate …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
